期刊
JOURNAL OF PROTEOMICS
卷 107, 期 -, 页码 50-55出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jprot.2014.02.034
关键词
Chemical proteomics; Oncology; Inflammation; Mass spectrometry; Antibody-phage libraries
资金
- ETH Zurich [LZ03463]
- Schweizerischer Nationalfonds (SNF) [310030_144091]
- EU [305309]
- Swiss Federal Commission for Technology and Innovation (KTI) [12803.1]
- Swiss National Science Foundation (SNF) [310030_144091] Funding Source: Swiss National Science Foundation (SNF)
Conventional chemotherapy of serious conditions (e.g., cancer and chronic inflammatory diseases) relies on the use of potent bioactive agents, which do not preferentially localize at the site of disease and which may harm healthy tissues. Intense pharmaceutical research efforts are being devoted to the development of targeted therapeutic agents, capable of selectively homing to diseased tissues, while sparing normal body structures. Biological mass spectrometry and chemical proteomics have revolutionized the way targets for ligand-based pharmacodelivery applications are discovered. In this article, we present a personal account on research activities in the field for the last decade, outlining our experience in the discovery of accessible biomarkers and in the development of potent targeted therapeutic agents. Biological significance The present review discusses evolution of proteomic methodologies applied to the discovery of new targets for therapeutic intervention in cancer and inflammatory diseases. Chemical proteomics-driven target discovery allowed the development of new classes of antibody-based targeting biologics, which are having an impact in the oncological and chronic inflammation clinical research. (C) 2014 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据